The major emphasis is on financial analysis. There are no fields that allow left truncation in this file. Any combination of display formats listed below can be used to display or print answers. The fields are displayed in the order requested. No online display fee for this format.
Custom display only.
Amgen has presented several papers relating to MGDF, a platelet growth factor used to create more platelets in the context of chemotherapy. A study using MGDF for breast cancer patients failed to show clinical efficacy for the compound. A study using the compound for peripheral blood transplants, in conjunction with very potent chemotherapy, seemed to show benefit. The company presented results for KGF, or keratinocyte growth factor, for mucositis. In one phase II study, M-195 was used to treat leukemia patients in remission.